コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 olinium enhancement identified the extent of myocardial necrosis.
2 ay cause arterial thrombosis with consequent myocardial necrosis.
3 e platelet aggregation in the ventricles and myocardial necrosis.
4 present in 69 patients, and 41 of 69 showed myocardial necrosis.
5 ocardial staining to define area at risk and myocardial necrosis.
6 haracterized by microvascular thrombosis and myocardial necrosis.
7 her there was a nonischemic pathogenesis for myocardial necrosis.
8 between the extent of myocardium at risk and myocardial necrosis.
9 differentiation of myocardial stunning from myocardial necrosis.
10 tal with acute coronary syndrome may signify myocardial necrosis.
11 gory of CABG and considered as high risk for myocardial necrosis.
12 ts anti-inflammatory activity or by reducing myocardial necrosis.
13 to the hospital who had no evidence of acute myocardial necrosis.
14 ate postischemic ventricular arrhythmias and myocardial necrosis.
15 r reperfusion and increased infarct size and myocardial necrosis.
16 did not sensitize mice to radiation-induced myocardial necrosis.
17 ar smooth muscle relaxant prevented onset of myocardial necrosis.
18 ltration occurs, occasionally accompanied by myocardial necrosis.
19 chloride (TTC) staining was used to identify myocardial necrosis.
20 chnique alone for identifying the absence of myocardial necrosis.
21 cardial reperfusion and experience extensive myocardial necrosis.
25 o contribute to both cardiac dysfunction and myocardial necrosis after reperfusion of an ischemic hea
26 have reported elevated levels of markers of myocardial necrosis among critically ill patients, the a
28 rtum females by 6 months of age, when severe myocardial necrosis and fibrosis and extensive dystrophi
29 renal dysfunction, neurohumoral activation, myocardial necrosis and fibrosis biomarkers, and the sev
30 ease of inflammatory cytokines) and in vivo (myocardial necrosis and fibrosis, left ventricular contr
32 less than 4.0 hours was critical in reducing myocardial necrosis and improving heart function and 30-
33 MR can predict subsequent risk of developing myocardial necrosis and may guide adjunctive prevention
35 latory perfusion as the basis to distinguish myocardial necrosis and viability in the post-infarct st
37 inant of reactive oxygen species generation, myocardial necrosis, and left ventricular function follo
38 cardiac dysfunction was not associated with myocardial necrosis, apoptosis, inflammation, or mitocho
39 reconditioning response would result in less myocardial necrosis as assessed by postprocedure creatin
40 dial ischemia-reperfusion (AMI/R) injury and myocardial necrosis, as well as its correlation with int
43 duces superior platelet inhibition and lower myocardial necrosis compared with high-dose (600 mg) or
44 dels to significantly diminish the extent of myocardial necrosis consequent to coronary occlusion.
46 ts showed extensive endothelial cell damage, myocardial necrosis, fibrin deposition, and other signs
48 lar endothelial NO production and attenuates myocardial necrosis following ischemia and reperfusion i
49 rcellular adhesion molecule-1 also minimizes myocardial necrosis following ischemia and reperfusion.
50 requency energy is used to create a targeted myocardial necrosis for the treatment of various arrhyth
51 ase) lowering the threshold of detection for myocardial necrosis from 0.20 to 0.05 ng/mL with a sensi
53 at risk for cardiac events in the absence of myocardial necrosis, highlighting its potential usefulne
55 vation prevents vascular renarrowing per se, myocardial necrosis impairs the clinical manifestation o
57 on are critical to reduce the progression of myocardial necrosis, in which proteolytic degradation of
58 eads again to vascular dysfunction and acute myocardial necrosis, indicating that predilection for ca
63 ologic basis for differential enhancement of myocardial necrosis is the greater distribution volume o
64 n of inflammatory activity and the extent of myocardial necrosis itself are of great clinical and pro
65 contractile dysfunction without significant myocardial necrosis (left ventricular pressure-volume cu
67 r computed tomography (MDCT) for quantifying myocardial necrosis, microvascular obstruction, and chro
69 cute coronary syndromes may be a response to myocardial necrosis or may reflect the inflammatory proc
71 hemia-reperfusion also experienced increased myocardial necrosis (P<0.01 versus control diet), which
73 10 min before R significantly inhibited the myocardial necrosis seen 4.5 h post-R compared with that
74 rades circulating catecholamines and reduces myocardial necrosis, suggesting that it may protect agai
75 (common in high-voltage electrical injury), myocardial necrosis, the level of central nervous system
76 te gadolinium enhancement was used to depict myocardial necrosis; these imaging experiments were also
80 h radionuclide ventriculography (n = 8), and myocardial necrosis was looked for with trichlorotetrazo
82 he difference between myocardium at risk and myocardial necrosis, was associated with regional and gl
83 function, extent of myocardium at risk, and myocardial necrosis were quantified by cardiac magnetic
84 o-enzyme A (CoA) reductase inhibitor, limits myocardial necrosis when administered as an adjunct to r
85 f attenuated periprocedural inflammation and myocardial necrosis with a strategy of GP IIb/IIIa inhib
86 trategy (MMS) testing for several markers of myocardial necrosis with different time-to-positivity pr
88 ials should ensure systematic evaluation for myocardial necrosis, with attention paid to multivariabl
89 lity and (2) the occurrence of perioperative myocardial necrosis would affect late regional wall moti